2026-527268-33-00Not yet recruitingPhase 1
PANVIRAL: Safety, Feasibility and Immunogenicity of Intra-Tumoral ORCA-010 Oncolytic Virus Administration in Metastatic Pancreatic Cancer – A Single-Center Phase 1 Trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Oct 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 22 Jun 2026
- Start date
- 1 Jan 2027
- Lead sponsor
- Amsterdam UMC Stichting
- Diseases
- Pancreatic cancer
- EU CT number
- 2026-527268-33-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic pancreatic cancer to test the safety and immune response of ORCA-010, an oncolytic virus injected into the tumor.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Metastatic pancreatic cancer
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.